RE:RE:RE:RE:Adstiladrin has BlockBuster Potential...Yes, while at times I fret over the ongoing liquidity needs and the paltry private placements that come in dribs and drabs, it's worth remembering the bigger picture, which is why we are all here.
An ideal roadmap would be ruvidar being granted BTD by Q1, or sooner. This achievement should hasten partner discussions/negotiations and result in a re-rating of the stock price bringing all outstanding warrants itm. This would also likely bring an end to the begging bowl fundings that have mired the stock price and frustrated investors immensely.
But the real buyout value of this company is not just with NMIBC's $1.1 - $5B global annual peak sales potential; it is "swinging for the fences" and advancing the pipeline (NSCLC and GBM) to at least ph1 results success, offering a suitor the promise of a foundational and transformative technology, enabling a premium buyout offer for investors.